Hims & Hers HUGE Acquisition News!
Key Points
Eucalyptus will add $450 million in annual revenue growing at a triple digit rate to Hims & Hers.
The risk is in using the $1 billion in cash on the balance sheet to buy more growth.
Management isn't shying away from the risks currently facing the business.
- 10 stocks we like better than Hims & Hers Health ›
Hims & Hers (NYSE: HIMS) announced the $1.15 billion acquisition of Australian telehealth company Eucalyptus, which will add $450 million in annualized revenue to the company. This isn't a company shying away from recent legal action, it's scaling internationally as fast as possible. In this video, I go through the upside from this acquisition as well as the downside of using most of the cash on the balance sheet, which was once a backstop for investors.
*Stock prices used were end-of-day prices of Feb. 19, 2026. The video was published on Feb. 19, 2026.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Should you buy stock in Hims & Hers Health right now?
Before you buy stock in Hims & Hers Health, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Hims & Hers Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $420,595!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,152,356!*
Now, it’s worth noting Stock Advisor’s total average return is 899% — a market-crushing outperformance compared to 194% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of February 19, 2026.
Travis Hoium has positions in Hims & Hers Health. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Travis Hoium is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool.
Recommended Articles
